All stock lists
Mineralys Therapeutics, Inc. (NASDAQ:MLYS)
US · Delayed Price · Currency is USD
20.55-0.92 (-4.29%)
Insider Score
––Not scored
MLYS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
MLYS Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 6.00 K | 0.00 | 15.00 K | 0.00 | 0.00 |
| Gross Profit | 0.00 | -6.00 K | 0.00 | -15.00 K | 0.00 | 0.00 |
| SG&A Expense | 24.66 M | 20.98 M | 13.88 M | 9.68 M | 8.47 M | 6.57 M |
| R&D Expense | 221.38 M | 24.36 M | 24.40 M | 31.45 M | 38.28 M | 37.88 M |
| Operating Expenses | 246.04 M | 45.34 M | 38.28 M | 41.12 M | 46.75 M | 44.45 M |
| Operating Income | -246.04 M | -45.34 M | -38.28 M | -41.13 M | -46.75 M | -44.45 M |
| Pretax Income | -241.07 M | -39.34 M | -32.23 M | -36.93 M | -43.27 M | -42.21 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -241.07 M | -39.34 M | -32.23 M | -36.93 M | -43.27 M | -42.21 M |
| EPS (Basic) | -2.85 | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 |
| EPS (Diluted) | -2.85 | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 |
| Shares Outstanding | 84.73 M | 82.83 M | 80.55 M | 70.59 M | 65.45 M | 53.16 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.